A randomized, double-blind study comparing LY2216684 and placebo in the treatment of major depressive disorder
The efficacy, tolerability, and safety of LY2216684, a highly selective norepinephrine reuptake inhibitor, were studied in adult patients with major depressive disorder (MDD). This randomized, double-blind study compared flexible-dose LY2216684 6–18 mg once daily (N = 250) with placebo (N = 245) for...
Saved in:
| Published in | Journal of psychiatric research Vol. 45; no. 6; pp. 748 - 755 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Kidlington
Elsevier Ltd
01.06.2011
Elsevier |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The efficacy, tolerability, and safety of LY2216684, a highly selective norepinephrine reuptake inhibitor, were studied in adult patients with major depressive disorder (MDD). This randomized, double-blind study compared flexible-dose LY2216684 6–18 mg once daily (N = 250) with placebo (N = 245) for 10 weeks acute therapy followed by 1 year LY2216684 treatment (results not reported here). Primary inclusion criteria consisted of GRID 17-item Hamilton Rating Scale for Depression total score ≥18 and Clinical Global Impressions-Severity score ≥4. The primary efficacy measure was the Montgomery-Asberg Depression Rating Scale (MADRS) total score. Response was defined as a ≥50% reduction in MADRS score and remission as MADRS total score ≤10. Global functioning was assessed using the Sheehan Disability Scale (SDS). LY2216684-treated patients showed significant improvement from baseline on the MADRS total score compared with placebo-treated patients (−13.3 vs. −9.8, p < .001), and they had a significantly higher probability of achieving response (49.5%) and remission (29.7%) compared with placebo-treated patients (29.3% and 18.8%, respectively). For the SDS global functional impairment score, LY2216684 treatment resulted in significantly greater improvement compared with placebo treatment (p < .001). More LY2216684-treated than placebo-treated patients discontinued from the study because of an adverse event or death (9.6% vs. 1.6%, p ≤ .001). LY2216684 was associated with significant increases (p < .01) from baseline in systolic (3 mm Hg) and diastolic (4 mm Hg) blood pressure and pulse (10 bpm) compared with placebo. LY2216684 6–18 mg demonstrated significant efficacy and was tolerated in the treatment of MDD. |
|---|---|
| AbstractList | The efficacy, tolerability, and safety of LY2216684, a highly selective norepinephrine reuptake inhibitor, were studied in adult patients with major depressive disorder (MDD). This randomized, double-blind study compared flexible-dose LY2216684 6-18 mg once daily (N = 250) with placebo (N = 245) for 10 weeks acute therapy followed by 1 year LY2216684 treatment (results not reported here). Primary inclusion criteria consisted of GRID 17-item Hamilton Rating Scale for Depression total score ≥18 and Clinical Global Impressions-Severity score ≥4. The primary efficacy measure was the Montgomery-Asberg Depression Rating Scale (MADRS) total score. Response was defined as a ≥50% reduction in MADRS score and remission as MADRS total score ≤10. Global functioning was assessed using the Sheehan Disability Scale (SDS). LY2216684-treated patients showed significant improvement from baseline on the MADRS total score compared with placebo-treated patients (-13.3 vs. -9.8, p < .001), and they had a significantly higher probability of achieving response (49.5%) and remission (29.7%) compared with placebo-treated patients (29.3% and 18.8%, respectively). For the SDS global functional impairment score, LY2216684 treatment resulted in significantly greater improvement compared with placebo treatment (p < .001). More LY2216684-treated than placebo-treated patients discontinued from the study because of an adverse event or death (9.6% vs. 1.6%, p ≤ .001). LY2216684 was associated with significant increases (p < .01) from baseline in systolic (3 mm Hg) and diastolic (4 mm Hg) blood pressure and pulse (10 bpm) compared with placebo. LY2216684 6-18 mg demonstrated significant efficacy and was tolerated in the treatment of MDD.The efficacy, tolerability, and safety of LY2216684, a highly selective norepinephrine reuptake inhibitor, were studied in adult patients with major depressive disorder (MDD). This randomized, double-blind study compared flexible-dose LY2216684 6-18 mg once daily (N = 250) with placebo (N = 245) for 10 weeks acute therapy followed by 1 year LY2216684 treatment (results not reported here). Primary inclusion criteria consisted of GRID 17-item Hamilton Rating Scale for Depression total score ≥18 and Clinical Global Impressions-Severity score ≥4. The primary efficacy measure was the Montgomery-Asberg Depression Rating Scale (MADRS) total score. Response was defined as a ≥50% reduction in MADRS score and remission as MADRS total score ≤10. Global functioning was assessed using the Sheehan Disability Scale (SDS). LY2216684-treated patients showed significant improvement from baseline on the MADRS total score compared with placebo-treated patients (-13.3 vs. -9.8, p < .001), and they had a significantly higher probability of achieving response (49.5%) and remission (29.7%) compared with placebo-treated patients (29.3% and 18.8%, respectively). For the SDS global functional impairment score, LY2216684 treatment resulted in significantly greater improvement compared with placebo treatment (p < .001). More LY2216684-treated than placebo-treated patients discontinued from the study because of an adverse event or death (9.6% vs. 1.6%, p ≤ .001). LY2216684 was associated with significant increases (p < .01) from baseline in systolic (3 mm Hg) and diastolic (4 mm Hg) blood pressure and pulse (10 bpm) compared with placebo. LY2216684 6-18 mg demonstrated significant efficacy and was tolerated in the treatment of MDD. The efficacy, tolerability, and safety of LY2216684, a highly selective norepinephrine reuptake inhibitor, were studied in adult patients with major depressive disorder (MDD). This randomized, double-blind study compared flexible-dose LY2216684 6–18 mg once daily (N = 250) with placebo (N = 245) for 10 weeks acute therapy followed by 1 year LY2216684 treatment (results not reported here). Primary inclusion criteria consisted of GRID 17-item Hamilton Rating Scale for Depression total score ≥18 and Clinical Global Impressions-Severity score ≥4. The primary efficacy measure was the Montgomery-Asberg Depression Rating Scale (MADRS) total score. Response was defined as a ≥50% reduction in MADRS score and remission as MADRS total score ≤10. Global functioning was assessed using the Sheehan Disability Scale (SDS). LY2216684-treated patients showed significant improvement from baseline on the MADRS total score compared with placebo-treated patients (−13.3 vs. −9.8, p < .001), and they had a significantly higher probability of achieving response (49.5%) and remission (29.7%) compared with placebo-treated patients (29.3% and 18.8%, respectively). For the SDS global functional impairment score, LY2216684 treatment resulted in significantly greater improvement compared with placebo treatment (p < .001). More LY2216684-treated than placebo-treated patients discontinued from the study because of an adverse event or death (9.6% vs. 1.6%, p ≤ .001). LY2216684 was associated with significant increases (p < .01) from baseline in systolic (3 mm Hg) and diastolic (4 mm Hg) blood pressure and pulse (10 bpm) compared with placebo. LY2216684 6–18 mg demonstrated significant efficacy and was tolerated in the treatment of MDD. Abstract The efficacy, tolerability, and safety of LY2216684, a highly selective norepinephrine reuptake inhibitor, were studied in adult patients with major depressive disorder (MDD). This randomized, double-blind study compared flexible-dose LY2216684 6–18 mg once daily ( N = 250) with placebo ( N = 245) for 10 weeks acute therapy followed by 1 year LY2216684 treatment (results not reported here). Primary inclusion criteria consisted of GRID 17-item Hamilton Rating Scale for Depression total score ≥18 and Clinical Global Impressions-Severity score ≥4. The primary efficacy measure was the Montgomery-Asberg Depression Rating Scale (MADRS) total score. Response was defined as a ≥50% reduction in MADRS score and remission as MADRS total score ≤10. Global functioning was assessed using the Sheehan Disability Scale (SDS). LY2216684-treated patients showed significant improvement from baseline on the MADRS total score compared with placebo-treated patients (−13.3 vs. −9.8, p < .001), and they had a significantly higher probability of achieving response (49.5%) and remission (29.7%) compared with placebo-treated patients (29.3% and 18.8%, respectively). For the SDS global functional impairment score, LY2216684 treatment resulted in significantly greater improvement compared with placebo treatment ( p < .001). More LY2216684-treated than placebo-treated patients discontinued from the study because of an adverse event or death (9.6% vs. 1.6%, p ≤ .001). LY2216684 was associated with significant increases ( p < .01) from baseline in systolic (3 mm Hg) and diastolic (4 mm Hg) blood pressure and pulse (10 bpm) compared with placebo. LY2216684 6–18 mg demonstrated significant efficacy and was tolerated in the treatment of MDD. The efficacy, tolerability, and safety of LY2216684, a highly selective norepinephrine reuptake inhibitor, were studied in adult patients with major depressive disorder (MDD). This randomized, double-blind study compared flexible-dose LY2216684 6-18 mg once daily (N = 250) with placebo (N = 245) for 10 weeks acute therapy followed by 1 year LY2216684 treatment (results not reported here). Primary inclusion criteria consisted of GRID 17-item Hamilton Rating Scale for Depression total score ≥18 and Clinical Global Impressions-Severity score ≥4. The primary efficacy measure was the Montgomery-Asberg Depression Rating Scale (MADRS) total score. Response was defined as a ≥50% reduction in MADRS score and remission as MADRS total score ≤10. Global functioning was assessed using the Sheehan Disability Scale (SDS). LY2216684-treated patients showed significant improvement from baseline on the MADRS total score compared with placebo-treated patients (-13.3 vs. -9.8, p < .001), and they had a significantly higher probability of achieving response (49.5%) and remission (29.7%) compared with placebo-treated patients (29.3% and 18.8%, respectively). For the SDS global functional impairment score, LY2216684 treatment resulted in significantly greater improvement compared with placebo treatment (p < .001). More LY2216684-treated than placebo-treated patients discontinued from the study because of an adverse event or death (9.6% vs. 1.6%, p ≤ .001). LY2216684 was associated with significant increases (p < .01) from baseline in systolic (3 mm Hg) and diastolic (4 mm Hg) blood pressure and pulse (10 bpm) compared with placebo. LY2216684 6-18 mg demonstrated significant efficacy and was tolerated in the treatment of MDD. The efficacy, tolerability, and safety of LY2216684, a highly selective norepinephrine reuptake inhibitor, were studied in adult patients with major depressive disorder (MDD). This randomized, double-blind study compared flexible-dose LY2216684 6-18 mg once daily (N = 250) with placebo (N = 245) for 10 weeks acute therapy followed by 1 year LY2216684 treatment (results not reported here). Primary inclusion criteria consisted of GRID 17-item Hamilton Rating Scale for Depression total score =18 and Clinical Global Impressions-Severity score =4. The primary efficacy measure was the Montgomery-Asberg Depression Rating Scale (MADRS) total score. Response was defined as a =50% reduction in MADRS score and remission as MADRS total score =10. Global functioning was assessed using the Sheehan Disability Scale (SDS). LY2216684-treated patients showed significant improvement from baseline on the MADRS total score compared with placebo-treated patients (-13.3 vs. -9.8, p < .001), and they had a significantly higher probability of achieving response (49.5%) and remission (29.7%) compared with placebo-treated patients (29.3% and 18.8%, respectively). For the SDS global functional impairment score, LY2216684 treatment resulted in significantly greater improvement compared with placebo treatment (p < .001). More LY2216684-treated than placebo-treated patients discontinued from the study because of an adverse event or death (9.6% vs. 1.6%, p = .001). LY2216684 was associated with significant increases (p < .01) from baseline in systolic (3 mm Hg) and diastolic (4 mm Hg) blood pressure and pulse (10 bpm) compared with placebo. LY2216684 6-18 mg demonstrated significant efficacy and was tolerated in the treatment of MDD. [Copyright Elsevier Ltd.] |
| Author | Dellva, Mary Anne D’Souza, Deborah N. Pangallo, Beth Essink, Beal Russell, James Goldberger, Celine |
| Author_xml | – sequence: 1 givenname: Beth surname: Pangallo fullname: Pangallo, Beth email: pangallo_beth_a@lilly.com organization: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA – sequence: 2 givenname: Mary Anne surname: Dellva fullname: Dellva, Mary Anne organization: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA – sequence: 3 givenname: Deborah N. surname: D’Souza fullname: D’Souza, Deborah N. organization: i3 Statprobe, Ann Arbor, MI 48108, USA – sequence: 4 givenname: Beal surname: Essink fullname: Essink, Beal organization: Oregon Center Clinical Investigation, 702 Church Street North East, Salem, OR 97301, USA – sequence: 5 givenname: James surname: Russell fullname: Russell, James organization: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA – sequence: 6 givenname: Celine surname: Goldberger fullname: Goldberger, Celine organization: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24212243$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/21511276$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkl1rFDEYhYNU7Lb6FyQ3ohfOmI-ZZPamWItfsOCFCnoVMsk7NuNMMk1mCuuvN8tuKRSUhUBunve8yTnnDJ344AEhTElJCRVv-rKf0tZcuwipZITSkvCS0OoRWtFGrgvK5foErQhhrODrWpyis5R6QohktHqCThmtKWVSrJC_xFF7G0b3B-xrbMPSDlC0g_MWp3mxW2zCOOno_C-8-ckYFaKpcJ7A06ANtAE7j-drwHMEPY_gZxw6POo-RGxhyu9L7hawdSlEC_EpetzpIcGzw32Ovn94_-3qU7H58vHz1eWmMHXVzEVT8xpqq5nmtTSayla0VHas1eu1YLKzHRUNdC2p87FWUAJVR5lhTNqW6Yafo5d73SmGmwXSrEaXDAyD9hCWpBohOeOMkEy--i-Z_SaSNFXFMvr8gC7tCFZN0Y06btWdmxl4cQB0MnrosrPGpXuuYpSximfuYs-ZGFKK0CnjZj274Oeo3ZB37tYK1av7mNUuZkW4yjFngeaBwN2OI0bf7Uch23_rIKpkHHgDNqNmVja4Y0QuHoiY3BiX__wbtpD6sESf41VUJaaI-ror4q6HlOYOCv4jC7z9t8Bxb_gLMwbyrQ |
| CODEN | JPYRA3 |
| CitedBy_id | crossref_primary_10_1089_cap_2012_0016 crossref_primary_10_1021_acs_chemrev_5b00392 crossref_primary_10_1089_cap_2016_0110 crossref_primary_10_1016_j_immuni_2023_02_002 crossref_primary_10_1185_03007995_2015_1037732 crossref_primary_10_1517_13543784_2014_985784 crossref_primary_10_1517_17425255_2014_939955 crossref_primary_10_3389_fphar_2022_884143 crossref_primary_10_1517_14728214_2012_660146 crossref_primary_10_1517_14728214_2012_681301 crossref_primary_10_1016_j_jad_2014_06_006 crossref_primary_10_1021_ol503425t crossref_primary_10_1002_ejoc_202000368 crossref_primary_10_1002_jcph_551 crossref_primary_10_1007_s40263_015_0294_3 crossref_primary_10_1007_s00228_013_1572_y crossref_primary_10_1176_appi_focus_10_4_452 crossref_primary_10_1089_cap_2011_0151 crossref_primary_10_4236_ojpsych_2014_42017 crossref_primary_10_4103_1673_5374_235019 crossref_primary_10_1016_j_tetlet_2021_153394 crossref_primary_10_1016_j_euroneuro_2014_12_009 |
| Cites_doi | 10.1016/S0006-3223(02)01866-8 10.1002/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N 10.1176/appi.ajp.163.1.28 10.4088/JCP.v67n1113 10.1097/YIC.0b013e3282f948f5 10.1586/14737175.7.10.1251 10.3928/0048-5713-19940601-07 10.1016/0168-8510(90)90421-9 10.1016/j.jad.2004.09.008 10.1136/jnnp.23.1.56 10.1097/00005053-199906000-00005 10.1192/bjp.134.4.382 10.1016/j.jpsychires.2009.09.013 10.1002/da.20642 10.1001/jama.289.23.3095 |
| ContentType | Journal Article |
| Copyright | 2011 Elsevier Ltd Elsevier Ltd 2015 INIST-CNRS Copyright © 2011 Elsevier Ltd. All rights reserved. |
| Copyright_xml | – notice: 2011 Elsevier Ltd – notice: Elsevier Ltd – notice: 2015 INIST-CNRS – notice: Copyright © 2011 Elsevier Ltd. All rights reserved. |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7QJ 7X8 |
| DOI | 10.1016/j.jpsychires.2011.03.014 |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Applied Social Sciences Index & Abstracts (ASSIA) MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Applied Social Sciences Index and Abstracts (ASSIA) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE Applied Social Sciences Index and Abstracts (ASSIA) |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1879-1379 |
| EndPage | 755 |
| ExternalDocumentID | 21511276 24212243 10_1016_j_jpsychires_2011_03_014 S002239561100063X 1_s2_0_S002239561100063X |
| Genre | Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- --K --M .1- .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29L 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 71M 8P~ 9JM 9JO AABNK AADFP AAEDT AAEDW AAGJA AAGUQ AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATTM AAXKI AAXLA AAXUO AAYWO ABBQC ABCQJ ABFNM ABIVO ABJNI ABLJU ABMAC ABMZM ABOYX ABPPZ ABWVN ABXDB ACDAQ ACGFS ACHQT ACIEU ACIUM ACNCT ACRLP ACRPL ACVFH ACXNI ADBBV ADCNI ADEZE ADMUD ADNMO ADXHL AEBSH AEIPS AEKER AENEX AEUPX AEVXI AFJKZ AFPUW AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AGUBO AGWIK AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HEG HF~ HMK HMO HMQ HMW HVGLF HZ~ IHE J1W K-O KOM L7B M29 M2V M39 M3V M41 MO0 MOBAO N9A O-L O9- OAUVE OH0 OKEIE OU- OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SNS SPCBC SPS SSB SSH SSN SSY SSZ T5K WUQ YQT Z5R ZGI ~G- AACTN AFCTW AFKWA AJOXV AMFUW PKN RIG AADPK AAIAV ABLVK ABYKQ AFYLN AJBFU EFLBG LCYCR ZA5 AAYXX AGRNS CITATION IQODW CGR CUY CVF ECM EIF NPM 7QJ 7X8 |
| ID | FETCH-LOGICAL-c548t-8535e5da2a357ca17b6b17f2ba99627fdf168efb05b05dd610e4f12c227db2a83 |
| IEDL.DBID | .~1 |
| ISSN | 0022-3956 1879-1379 |
| IngestDate | Fri Jul 11 16:06:46 EDT 2025 Tue Aug 05 11:11:11 EDT 2025 Thu Apr 03 06:49:22 EDT 2025 Mon Jul 21 09:18:05 EDT 2025 Tue Jul 01 01:03:44 EDT 2025 Thu Apr 24 22:53:48 EDT 2025 Fri Feb 23 02:28:06 EST 2024 Sun Feb 23 10:18:44 EST 2025 Tue Aug 26 20:35:43 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | Efficacy Norepinephrine Safety Major depressive disorder LY2216684 Mood disorder Treatment Placebo Neurotransmitter Double blind study Depression Catecholamine |
| Language | English |
| License | https://www.elsevier.com/tdm/userlicense/1.0 CC BY 4.0 Copyright © 2011 Elsevier Ltd. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c548t-8535e5da2a357ca17b6b17f2ba99627fdf168efb05b05dd610e4f12c227db2a83 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| PMID | 21511276 |
| PQID | 1010708442 |
| PQPubID | 24071 |
| PageCount | 8 |
| ParticipantIDs | proquest_miscellaneous_867323200 proquest_miscellaneous_1010708442 pubmed_primary_21511276 pascalfrancis_primary_24212243 crossref_citationtrail_10_1016_j_jpsychires_2011_03_014 crossref_primary_10_1016_j_jpsychires_2011_03_014 elsevier_sciencedirect_doi_10_1016_j_jpsychires_2011_03_014 elsevier_clinicalkeyesjournals_1_s2_0_S002239561100063X elsevier_clinicalkey_doi_10_1016_j_jpsychires_2011_03_014 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2011-06-01 |
| PublicationDateYYYYMMDD | 2011-06-01 |
| PublicationDate_xml | – month: 06 year: 2011 text: 2011-06-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Kidlington |
| PublicationPlace_xml | – name: Kidlington – name: England |
| PublicationTitle | Journal of psychiatric research |
| PublicationTitleAlternate | J Psychiatr Res |
| PublicationYear | 2011 |
| Publisher | Elsevier Ltd Elsevier |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier |
| References | [APA] American Psychiatric Association (bib1) 1994 Dubé, Dellva, Jones, Kielbasa, Padich, Saha (bib4) 2010; 44 (bib5) 2008 [FDA] Food & Drug Administration (bib10) 2009 Marcus, Young, Kerber, Kornstein, Farabaugh, Mitchell (bib19) 2005; 87 Greden (bib13) 2002; 63 Stahl, Zhang, Damatarca, Grady (bib31) 2003; 64 Kielbasa, Quinlan, Lachno, Bredt, Dubé (bib16) 2010 Sheehan (bib29) 1983 Fava, Kaji (bib9) 1994; 24 Kessler, Berglund, Demler, Jin, Koretz, Merikangas (bib17) 2003; 289 Guy (bib14) 1976 Hamilton (bib15) 1960; 23 [APA] American Psychiatric Association (bib2) 2000 Sartorius, Angstt (bib28) 2001; 16 Moos, Cronkite (bib23) 1999; 187 Phillips, Matza, Murray, Revicki (bib25) 2009; 16 (bib6) 2009 Montgomery, Asberg (bib21) 1979; 134 Montgomery (bib22) 1997; 11 Posner (bib26) 2007 Wolfe (bib34) 2004; 31 World Health Organization (bib35) 2010 Williams, Kobak, Bech, Engelhardt, Evans, Lipsitz (bib33) 2008; 23 Fava, Graves, Benazzi, Scalia, Iosifescu, Alpert (bib8) 2006; 67 (bib3) 2010 Mendoza, Wang, Cleeland, Morrissey, Johnson, Wendt (bib20) 1999; 85 Sheehan, Lecrubier, Sheehan, Amorim, Janavs, Weiller (bib30) 1998; 59 Rush, Trivedi, Ibrahim, Carmody, Arnow, Klein (bib27) 2003; 54 Trivedi, Rush, Wisniewski, Nierenberg, Warden, Ritz (bib32) 2006; 163 EuroQol (bib7) 1990; 16 Greden (bib12) 2001; 62 Pae, Lim, Han, Patkar, Steffens, Masand (bib24) 2007; 7 Goddard, Ball, Martinez, Robinson, Yang, Russell (bib11) 2010; 27 (bib18) 2009 Montgomery (10.1016/j.jpsychires.2011.03.014_bib22) 1997; 11 (10.1016/j.jpsychires.2011.03.014_bib18) 2009 Sheehan (10.1016/j.jpsychires.2011.03.014_bib29) 1983 (10.1016/j.jpsychires.2011.03.014_bib6) 2009 Goddard (10.1016/j.jpsychires.2011.03.014_bib11) 2010; 27 Sheehan (10.1016/j.jpsychires.2011.03.014_bib30) 1998; 59 Dubé (10.1016/j.jpsychires.2011.03.014_bib4) 2010; 44 Marcus (10.1016/j.jpsychires.2011.03.014_bib19) 2005; 87 Moos (10.1016/j.jpsychires.2011.03.014_bib23) 1999; 187 Hamilton (10.1016/j.jpsychires.2011.03.014_bib15) 1960; 23 Sartorius (10.1016/j.jpsychires.2011.03.014_bib28) 2001; 16 [FDA] Food & Drug Administration (10.1016/j.jpsychires.2011.03.014_bib10) 2009 Greden (10.1016/j.jpsychires.2011.03.014_bib13) 2002; 63 World Health Organization (10.1016/j.jpsychires.2011.03.014_bib35) 2010 Rush (10.1016/j.jpsychires.2011.03.014_bib27) 2003; 54 Fava (10.1016/j.jpsychires.2011.03.014_bib9) 1994; 24 Guy (10.1016/j.jpsychires.2011.03.014_bib14) 1976 Trivedi (10.1016/j.jpsychires.2011.03.014_bib32) 2006; 163 (10.1016/j.jpsychires.2011.03.014_bib3) 2010 Pae (10.1016/j.jpsychires.2011.03.014_bib24) 2007; 7 Williams (10.1016/j.jpsychires.2011.03.014_bib33) 2008; 23 Kessler (10.1016/j.jpsychires.2011.03.014_bib17) 2003; 289 Phillips (10.1016/j.jpsychires.2011.03.014_bib25) 2009; 16 Stahl (10.1016/j.jpsychires.2011.03.014_bib31) 2003; 64 Wolfe (10.1016/j.jpsychires.2011.03.014_bib34) 2004; 31 Greden (10.1016/j.jpsychires.2011.03.014_bib12) 2001; 62 (10.1016/j.jpsychires.2011.03.014_bib5) 2008 Kielbasa (10.1016/j.jpsychires.2011.03.014_bib16) 2010 Montgomery (10.1016/j.jpsychires.2011.03.014_bib21) 1979; 134 [APA] American Psychiatric Association (10.1016/j.jpsychires.2011.03.014_bib2) 2000 Fava (10.1016/j.jpsychires.2011.03.014_bib8) 2006; 67 [APA] American Psychiatric Association (10.1016/j.jpsychires.2011.03.014_bib1) 1994 EuroQol (10.1016/j.jpsychires.2011.03.014_bib7) 1990; 16 Posner (10.1016/j.jpsychires.2011.03.014_bib26) 2007 Mendoza (10.1016/j.jpsychires.2011.03.014_bib20) 1999; 85 |
| References_xml | – volume: 289 start-page: 3095 year: 2003 end-page: 3105 ident: bib17 article-title: National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the national Comorbidity Survey Replication (NCS-R) publication-title: Journal of the American Medical Association – volume: 16 start-page: 460 year: 2009 ident: bib25 article-title: Reliability and validity of the fatigue associated with depression questionnaire (FAsD): an interim analysis publication-title: European Journal of Neurology – volume: 16 start-page: 199 year: 1990 end-page: 208 ident: bib7 article-title: A new facility for the measurement of health-related quality of life publication-title: Health Policy – volume: 87 start-page: 141 year: 2005 end-page: 150 ident: bib19 article-title: Gender differences in depression: findings from the STAR∗D study publication-title: Journal of Affective Disorders – volume: 24 start-page: 281 year: 1994 end-page: 290 ident: bib9 article-title: Continuation and maintenance treatments of major depressive disorder publication-title: Psychiatric Annals – year: 2010 ident: bib3 article-title: Cymbalta [package insert] – volume: 54 start-page: 573 year: 2003 end-page: 583 ident: bib27 article-title: The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression publication-title: Biological Psychiatry – year: 2007 ident: bib26 article-title: State of the science: measurement of suicidal adverse events and the Columbia suicide severity rating scale – year: 1983 ident: bib29 article-title: The anxiety disease – volume: 16 year: 2001 ident: bib28 article-title: Suicide in population subgroups publication-title: International Clinical Psychopharmacology – year: 2010 ident: bib35 article-title: 2010 WHO Initiative on depression in Public health – year: 1994 ident: bib1 article-title: Diagnostic and statistical manual of mental disorders – volume: 64 start-page: 6 year: 2003 end-page: 17 ident: bib31 article-title: Brain circuits determine destiny in depression: a novel approach to the psychopharmacology of wakefulness, fatigue, and executive dysfunction in major depressive disorder publication-title: Journal of Clinical Psychiatry – year: 2008 ident: bib5 article-title: Edronax [package insert] – year: 2010 ident: bib16 article-title: Pharmacodynamics of LY2216684: evaluation of peripheral and central norepinephrine transporter inhibition using 3,4-dihydroxyphenylglycol as a biomarker of pharmacologic activity – year: 2009 ident: bib18 article-title: Lexapro [package insert] – volume: 7 start-page: 1251 year: 2007 end-page: 1263 ident: bib24 article-title: Fatigue as a core symptom in major depressive disorder: overview and the role of bupropion publication-title: Expert Review of Neurotherapeutics – volume: 23 start-page: 120 year: 2008 end-page: 129 ident: bib33 article-title: The GRID-HAMD: standardization of the Hamilton Depression Rating Scale publication-title: International Clinical Psychopharmacology – volume: 59 start-page: 22 year: 1998 end-page: 33 ident: bib30 article-title: The Mini International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10 publication-title: Journal of Clinical Psychiatry – volume: 63 start-page: 3 year: 2002 end-page: 7 ident: bib13 article-title: Unmet need: what justifies the search for a new antidepressant? publication-title: Journal of Clinical Psychiatry – volume: 31 start-page: 1896 year: 2004 end-page: 1902 ident: bib34 article-title: Fatigue assessments in rheumatoid arthritis: comparative performance of visual analog scales and longer fatigue questionnaires in 7760 patients publication-title: Journal of Rheumatology – volume: 134 start-page: 382 year: 1979 end-page: 389 ident: bib21 article-title: A new depression scale designed to be sensitive to change publication-title: British Journal of Psychiatry – volume: 23 start-page: 56 year: 1960 end-page: 62 ident: bib15 article-title: A rating scale for depression publication-title: Journal of Neurology, Neurosurgery, and Psychiatry – year: 2000 ident: bib2 article-title: Diagnostic and statistical manual of mental disorders – year: 2009 ident: bib10 article-title: Guidance for industry-patient-reported outcome measures: use in medical product development to support labeling claims – year: 1976 ident: bib14 article-title: Clinical global impressions ECDEU assessment manual for psychopharmacology, revised (DHEW Publ. No. ADM 76-338) – volume: 27 start-page: 339 year: 2010 end-page: 350 ident: bib11 article-title: Current perspectives of the roles of the central norepinephrine system in anxiety and depression publication-title: Depression and Anxiety – volume: 67 start-page: 1754 year: 2006 end-page: 1759 ident: bib8 article-title: A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment publication-title: Journal of Clinical Psychiatry – volume: 163 start-page: 28 year: 2006 end-page: 40 ident: bib32 article-title: STAR∗D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR∗D: implications for clinical practice publication-title: American Journal of Psychiatry – volume: 62 start-page: 26 year: 2001 end-page: 31 ident: bib12 article-title: The burden of disease for treatment-resistant depression publication-title: Journal of Clinical Psychiatry – volume: 11 start-page: S9 year: 1997 end-page: S15 ident: bib22 article-title: Reboxetine: additional benefits to the depressed patient publication-title: Journal of Psychopharmacology – volume: 44 start-page: 356 year: 2010 end-page: 363 ident: bib4 article-title: A study of the effects of LY2216684, a selective norepinephrine reuptake inhibitor, in the treatment of major depression publication-title: Journal of Psychiatric Research – year: 2009 ident: bib6 article-title: Effexor XR [package insert] – volume: 85 start-page: 1186 year: 1999 end-page: 1196 ident: bib20 article-title: The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory publication-title: Cancer – volume: 187 start-page: 360 year: 1999 end-page: 368 ident: bib23 article-title: Symptom-based predictors of a 10-year chronic course of treated depression publication-title: Journal of Nervous and Mental Disease – volume: 16 start-page: 460 issue: Suppl. 3 year: 2009 ident: 10.1016/j.jpsychires.2011.03.014_bib25 article-title: Reliability and validity of the fatigue associated with depression questionnaire (FAsD): an interim analysis publication-title: European Journal of Neurology – volume: 59 start-page: 22 issue: Suppl. 20 year: 1998 ident: 10.1016/j.jpsychires.2011.03.014_bib30 article-title: The Mini International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10 publication-title: Journal of Clinical Psychiatry – volume: 64 start-page: 6 issue: Suppl. 14 year: 2003 ident: 10.1016/j.jpsychires.2011.03.014_bib31 article-title: Brain circuits determine destiny in depression: a novel approach to the psychopharmacology of wakefulness, fatigue, and executive dysfunction in major depressive disorder publication-title: Journal of Clinical Psychiatry – volume: 54 start-page: 573 year: 2003 ident: 10.1016/j.jpsychires.2011.03.014_bib27 article-title: The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression publication-title: Biological Psychiatry doi: 10.1016/S0006-3223(02)01866-8 – year: 2009 ident: 10.1016/j.jpsychires.2011.03.014_bib18 – year: 2007 ident: 10.1016/j.jpsychires.2011.03.014_bib26 – volume: 85 start-page: 1186 year: 1999 ident: 10.1016/j.jpsychires.2011.03.014_bib20 article-title: The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory publication-title: Cancer doi: 10.1002/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N – volume: 163 start-page: 28 year: 2006 ident: 10.1016/j.jpsychires.2011.03.014_bib32 article-title: STAR∗D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR∗D: implications for clinical practice publication-title: American Journal of Psychiatry doi: 10.1176/appi.ajp.163.1.28 – year: 2010 ident: 10.1016/j.jpsychires.2011.03.014_bib3 – year: 1994 ident: 10.1016/j.jpsychires.2011.03.014_bib1 – volume: 67 start-page: 1754 year: 2006 ident: 10.1016/j.jpsychires.2011.03.014_bib8 article-title: A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment publication-title: Journal of Clinical Psychiatry doi: 10.4088/JCP.v67n1113 – volume: 31 start-page: 1896 year: 2004 ident: 10.1016/j.jpsychires.2011.03.014_bib34 article-title: Fatigue assessments in rheumatoid arthritis: comparative performance of visual analog scales and longer fatigue questionnaires in 7760 patients publication-title: Journal of Rheumatology – year: 1983 ident: 10.1016/j.jpsychires.2011.03.014_bib29 – volume: 23 start-page: 120 year: 2008 ident: 10.1016/j.jpsychires.2011.03.014_bib33 article-title: The GRID-HAMD: standardization of the Hamilton Depression Rating Scale publication-title: International Clinical Psychopharmacology doi: 10.1097/YIC.0b013e3282f948f5 – year: 2010 ident: 10.1016/j.jpsychires.2011.03.014_bib35 – volume: 63 start-page: 3 issue: Suppl. 2 year: 2002 ident: 10.1016/j.jpsychires.2011.03.014_bib13 article-title: Unmet need: what justifies the search for a new antidepressant? publication-title: Journal of Clinical Psychiatry – year: 1976 ident: 10.1016/j.jpsychires.2011.03.014_bib14 – volume: 11 start-page: S9 issue: 4 Suppl. year: 1997 ident: 10.1016/j.jpsychires.2011.03.014_bib22 article-title: Reboxetine: additional benefits to the depressed patient publication-title: Journal of Psychopharmacology – volume: 62 start-page: 26 issue: Suppl. 16 year: 2001 ident: 10.1016/j.jpsychires.2011.03.014_bib12 article-title: The burden of disease for treatment-resistant depression publication-title: Journal of Clinical Psychiatry – year: 2008 ident: 10.1016/j.jpsychires.2011.03.014_bib5 – year: 2010 ident: 10.1016/j.jpsychires.2011.03.014_bib16 – year: 2009 ident: 10.1016/j.jpsychires.2011.03.014_bib10 – volume: 7 start-page: 1251 year: 2007 ident: 10.1016/j.jpsychires.2011.03.014_bib24 article-title: Fatigue as a core symptom in major depressive disorder: overview and the role of bupropion publication-title: Expert Review of Neurotherapeutics doi: 10.1586/14737175.7.10.1251 – volume: 24 start-page: 281 year: 1994 ident: 10.1016/j.jpsychires.2011.03.014_bib9 article-title: Continuation and maintenance treatments of major depressive disorder publication-title: Psychiatric Annals doi: 10.3928/0048-5713-19940601-07 – volume: 16 start-page: 199 year: 1990 ident: 10.1016/j.jpsychires.2011.03.014_bib7 article-title: A new facility for the measurement of health-related quality of life publication-title: Health Policy doi: 10.1016/0168-8510(90)90421-9 – volume: 87 start-page: 141 year: 2005 ident: 10.1016/j.jpsychires.2011.03.014_bib19 article-title: Gender differences in depression: findings from the STAR∗D study publication-title: Journal of Affective Disorders doi: 10.1016/j.jad.2004.09.008 – volume: 16 issue: Suppl. 2 year: 2001 ident: 10.1016/j.jpsychires.2011.03.014_bib28 article-title: Suicide in population subgroups publication-title: International Clinical Psychopharmacology – volume: 23 start-page: 56 year: 1960 ident: 10.1016/j.jpsychires.2011.03.014_bib15 article-title: A rating scale for depression publication-title: Journal of Neurology, Neurosurgery, and Psychiatry doi: 10.1136/jnnp.23.1.56 – volume: 187 start-page: 360 year: 1999 ident: 10.1016/j.jpsychires.2011.03.014_bib23 article-title: Symptom-based predictors of a 10-year chronic course of treated depression publication-title: Journal of Nervous and Mental Disease doi: 10.1097/00005053-199906000-00005 – volume: 134 start-page: 382 year: 1979 ident: 10.1016/j.jpsychires.2011.03.014_bib21 article-title: A new depression scale designed to be sensitive to change publication-title: British Journal of Psychiatry doi: 10.1192/bjp.134.4.382 – volume: 44 start-page: 356 year: 2010 ident: 10.1016/j.jpsychires.2011.03.014_bib4 article-title: A study of the effects of LY2216684, a selective norepinephrine reuptake inhibitor, in the treatment of major depression publication-title: Journal of Psychiatric Research doi: 10.1016/j.jpsychires.2009.09.013 – year: 2009 ident: 10.1016/j.jpsychires.2011.03.014_bib6 – volume: 27 start-page: 339 year: 2010 ident: 10.1016/j.jpsychires.2011.03.014_bib11 article-title: Current perspectives of the roles of the central norepinephrine system in anxiety and depression publication-title: Depression and Anxiety doi: 10.1002/da.20642 – volume: 289 start-page: 3095 year: 2003 ident: 10.1016/j.jpsychires.2011.03.014_bib17 article-title: National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the national Comorbidity Survey Replication (NCS-R) publication-title: Journal of the American Medical Association doi: 10.1001/jama.289.23.3095 – year: 2000 ident: 10.1016/j.jpsychires.2011.03.014_bib2 |
| SSID | ssj0007214 |
| Score | 2.1229045 |
| Snippet | The efficacy, tolerability, and safety of LY2216684, a highly selective norepinephrine reuptake inhibitor, were studied in adult patients with major depressive... Abstract The efficacy, tolerability, and safety of LY2216684, a highly selective norepinephrine reuptake inhibitor, were studied in adult patients with major... |
| SourceID | proquest pubmed pascalfrancis crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 748 |
| SubjectTerms | Adolescent Adrenergic Uptake Inhibitors - administration & dosage Adrenergic Uptake Inhibitors - adverse effects Adult Adult and adolescent clinical studies Aged Antidepressive Agents - administration & dosage Antidepressive Agents - adverse effects Biological and medical sciences Depression Depressive Disorder, Major - drug therapy Depressive personality disorders Diagnostic and Statistical Manual of Mental Disorders Disability Discontinued Dose-Response Relationship, Drug Double-Blind Method Efficacy Female Humans LY2216684 Major depressive disorder Male Medical sciences Middle Aged Mood disorders Morpholines - administration & dosage Morpholines - adverse effects Norepinephrine Phenylethyl Alcohol - administration & dosage Phenylethyl Alcohol - adverse effects Phenylethyl Alcohol - analogs & derivatives Psychiatric Status Rating Scales Psychiatry Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Remission Safety Treatment Outcome Young Adult |
| Title | A randomized, double-blind study comparing LY2216684 and placebo in the treatment of major depressive disorder |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S002239561100063X https://www.clinicalkey.es/playcontent/1-s2.0-S002239561100063X https://dx.doi.org/10.1016/j.jpsychires.2011.03.014 https://www.ncbi.nlm.nih.gov/pubmed/21511276 https://www.proquest.com/docview/1010708442 https://www.proquest.com/docview/867323200 |
| Volume | 45 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1La9wwEB5CCqVQSt9x2i4q9FgnlixbNj0toWH7SE4NbE9CsiTYJbGXeLeHHPrbO7JlL6FdWCj4ZDx-SOP5PknfjAA-OIGYi7ASF6kSMadaxwWlVYxxMNe20CJxPhv54jKfXfGv82x-AGdDLoyXVYbY38f0LlqHM6ehNU9Xi4XP8UVo83mZtAPauc9g58J7-cnvrcwDRzh8rBiOVwc1T6_xWvaSYhzYhmKe6UlC-S6IerxSLTac63e82E1JO2g6fwpPAqck0_61n8GBrZ_Dw4uwav4C6inBm5nmZnFnzUdimo2-trFGgmlIV16W9Ep0RDHy_SdjNM8LTtCCdIot3ZBFTZAoklGVThpHbtSyuSWDkvaXJSYU8nwJV-eff5zN4rDPQlzheGUdI2JnNjOKqTQTlaJC55oKx7Qq_dY8zjiaF9bpJMPDGCRcljvKKsaE0UwV6Ss4rJvaHgFJVKIVzYrUlRSpgS5VJkqD1pq61CkbgRiaVlahCLnfC-NaDmqzpdx2ivSdIpNUYqdEQEfLVV-IYw-bcug9OSSaYmiUiBZ72Ip_2do2_OOtpLJlMpF_-WEEn0bLe66853Mn99xs_Nhu7Z7xNIL3g99JDAV-fUfVttm0_r4YwAvOWQRkxzVFLlIk0UkSweveZ7cPoJ58i_z4v97_DTzqp939RNVbOFzfbuw75G1rPel-zAk8mH75Nrv8A8KkQ2I |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1ba9swFD50KWyDMXbr5l06DfY4r5Z8kc2eQllJ1yRPLWRPQrIkSGjtUCd72K_fkS27lC0QGPjJ-PgiHZ_vk_SdI4DPliPmIqyEeSx5mFClwpzSMsQ4mCmTKx5Zl408m2eTq-THIl0cwGmfC-NklT72dzG9jdb-zIlvzZP1culyfBHaXF4mbYF28QAOXXWqdASH4_OLyXwIyDjISYai4WjgBT2dzGvVqYpxbOvrecZfI5rsQqkna9lg29lu04vdrLRFp7Nn8NTTSjLu3vw5HJjqBTyc-YXzl1CNCd5M1zfL30Z_IbreqmsTKuSYmrQVZkknRkcgI9OfjNEsyxOCFqQVbamaLCuCXJEMwnRSW3IjV_Ut6cW0vwzRvpbnK7g6-355Ogn9VgthiUOWTYignZpUSybjlJeScpUpyi1TsnC781htaZYbq6IUD62Rc5nEUlYyxrViMo-PYFTVlXkDJJKRkjTNY1tQZAeqkCkvNForamMrTQC8b1pR-jrkbjuMa9ELzlbirlOE6xQRxQI7JQA6WK67Whx72BR974k-1xSjo0DA2MOW_8vWNP43bwQVDROR-MsVA_g2WN7z5j2fe3zPzYaPbZfvWRIH8Kn3O4HRwC3xyMrU28bdF2N4niQsALLjmjzjMfLoKArgdeezdw-gjn_z7O1_vf9HeDS5nE3F9Hx-8Q4ed7Pwbt7qPYw2t1vzAWncRh373_QPr0tGEw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+randomized%2C+double-blind+study+comparing+LY2216684+and+placebo+in+the+treatment+of+major+depressive+disorder&rft.jtitle=Journal+of+psychiatric+research&rft.au=Pangallo%2C+Beth&rft.au=Dellva%2C+Mary+Anne&rft.au=D%E2%80%99Souza%2C+Deborah+N.&rft.au=Essink%2C+Beal&rft.date=2011-06-01&rft.pub=Elsevier+Ltd&rft.issn=0022-3956&rft.eissn=1879-1379&rft.volume=45&rft.issue=6&rft.spage=748&rft.epage=755&rft_id=info:doi/10.1016%2Fj.jpsychires.2011.03.014&rft.externalDocID=S002239561100063X |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F00223956%2FS0022395611X00055%2Fcov150h.gif |